Quick Answer
Theriva Biologics, Inc. reported Diluted EPS of $2.08 per share (loss) for fiscal year 2025.
Theriva Biologics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.08 | +89.1% |
| 2024 | -$19.03 | +33.2% |
| 2023 | -$28.48 | -2074.0% |
| 2022 | -$1.31 | +31.1% |
| 2021 | -$1.90 | -187.9% |
| 2020 | -$0.66 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.45 | +93.4% | +76.7% |
| June 30, 2025 | -$1.93 | +82.0% | -24.5% |
| March 31, 2025 | -$1.55 | +79.4% | +77.2% |
| September 30, 2024 | -$6.81 | -40.4% | +36.5% |
| June 30, 2024 | -$10.72 | -3052.9% | -42.4% |
| March 31, 2024 | -$7.53 | -2410.0% | -55.3% |
| September 30, 2023 | -$4.85 | -1516.7% | -1326.5% |
| June 30, 2023 | -$0.34 | -21.4% | -13.3% |
- Theriva Biologics, Inc. showed an increase of +89.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Theriva Biologics, Inc.’s diluted eps has declined by 215.2% (from $0.66 per share (loss) to $2.08 per share (loss)).
- The most recent figure is from Theriva Biologics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: